PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18474461-2	2008	Eighteen patients (median age 59 years) with advanced and therapy-refractory CTCL in stages IIB-IV were treated with TSEBT for the first time.	tsebt	117-122	TSPY like 2	Homo sapiens	77-81	
8646693-14	1996	CONCLUSIONS: The extent of skin involvement of patients with T3 CTCL is a prognostic indicator of disease free and overall survival for those who have been treated definitively with TSEBT.	tsebt	182-187	TSPY like 2	Homo sapiens	64-68